The deal includes an upfront payment plus milestone payments tied primarily to clinical and regulatory successes.
- RayThera focuses on discovering and advancing small-molecule therapies targeting inflammation across a range of immune-related conditions.
- This marks Biogen’s second major acquisition of the year.
- In March, Biogen announced the purchase of Apellis Pharmaceuticals for around $5.6 billion in cash, plus contingent value rights worth up to an additional $4 per share.
Shares of Biogen (BIIB) edged lower by about 0.4% in after-hours trading on Wednesday after the company announced a deal to acquire RayThera Inc., a San Diego-based company developing small-molecule anti-inflammatory drugs for immune-mediated diseases, in a transaction valued at up to $1 billion.
The deal includes an upfront payment plus milestone payments tied primarily to clinical and regulatory successes. It is expected to close in the third quarter of 2026, subject to customary regulatory approvals.
What RayThera Brings
RayThera focuses on discovering and advancing small-molecule therapies targeting inflammation across a range of immune-related conditions. The company’s pipeline includes multiple anti-inflammatory assets. Its lead candidate is on track to enter Phase 1 clinical testing in early Q3 2026.
Biogen will take full responsibility for further development, manufacturing and global commercialization of these programs after the deal closes. The acquisition is expected to broaden Biogen’s immunology efforts and open opportunities in new disease areas while adding promising early-stage candidates to its longer-term pipeline.
Priya Singhal, Biogen’s Executive Vice President and Head of Development, said, “With this acquisition, we are further deepening our pipeline in immunology by adding a suite of assets that can allow us to expand into new disease areas. We believe these assets can meaningfully contribute to our long-term pipeline potential and we’re excited about the opportunity to rapidly advance the first candidate into the clinic.”
Biogen’s Other Deals This Year
This marks Biogen’s second major acquisition of the year and continues a pattern of using M&A to strengthen its position in immunology and rare diseases.
In March, Biogen announced the purchase of Apellis Pharmaceuticals for around $5.6 billion in cash, plus contingent value rights worth up to an additional $4 per share tied to sales of one of the products. The Apellis acquisition significantly boosted Biogen’s near-term revenue outlook, accelerated its expansion into nephrology (kidney diseases) and added commercial-stage immunology assets, including Empaveli and Syfovre.
How Did BIIB Retail Traders React?
On Stocktwits, retail sentiment around BIIB stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.
BIIB stock has gained 12% this year.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<